Premessa e rilevanza
New trials and approvals of targeted therapy and immunotherapy have enriched the options for first-line systemic therapy of advanced and metastatic renal cell carcinoma, mainly clear-cell histology.
Questa versione in lingua รจ in sviluppo; le traduzioni verranno aggiunte progressivamente
New trials and approvals of targeted therapy and immunotherapy have enriched the options for first-line systemic therapy of advanced and metastatic renal cell carcinoma, mainly clear-cell histology.